The blood-ocular barrier system is formed by two main barriers: the blood-aqueous barrier and the blood-retinal barrier (BRB). The BRB is particularly tight and restrictive and is a physiological barrier that regulates ion, protein and water flux into and out of the retina. The BRB consists of inner and outer components, the inner BRB being formed of tight junctions between retinal capillary endothelial cells and the outer BRB of tight junctions between retinal pigment epithelial cells. The BRB is essential to maintaining the eye as a privileged site and is essential for normal visual function. Alterations of the BRB play a crucial role in the development of retinal diseases. The two most frequent and relevant retinal diseases, diabetic retinopathy and age-related macular degeneration (AMD), are directly associated with alterations of the BRB. Diabetic retinopathy is initiated by an alteration of the inner BRB and neovascular AMD is a result of an alteration of the outer BRB. Treatment of retinal diseases must also deal with the BRB either by using its specific transport mechanisms or by circumventing it through intravitreal injections.
The blood-ocular barriers include two main barrier systems -the blood-aqueous barrier and the blood-retinal barrier (BRB) -which are fundamental to keeping the eye as a privileged site in the body by regulating the contents of its inner fluids and preserving the internal ocular tissues from the variations that occur constantly in the whole circulation. The BRB, similar to the blood-brain barrier (BBB), is particularly tight and restrictive and is a physiological barrier that regulates ion, protein and water flux into and out of the retina. 2 The blood-ocular barriers must not only provide a suitable, highly regulated chemical environment for the avascular transparent tissues of the eye, but also serve as a drainage route for the waste products of the metabolic activity of the ocular tissues. It is also important to realise that once inside these barriers there are no major diffusional barriers between the extracellular fluid of the retina and adjacent vitreous humour; nor does the vitreous body itself significantly hinder the diffusional exchanges between the posterior chamber and the retinal extracellular fluid. This means that the functions of both barriers -the blood-aqueous barrier and the BRB -influence each other and must work in equilibrium. 
Blood-Retinal Barrier
The BRB consists of inner and outer components (inner BRB [iBRB] and outer BRB [oBRB]) and plays a fundamental role in the microenvironment of the retina and retinal neurons. It regulates fluids and molecular movement between the ocular vascular beds and retinal tissues and prevents leakage into the retina of macromolecules and other potentially harmful agents (see Figures 1 and 2) . 
Blood-Retinal Barrier and Retinal Diseases
An alteration of the iBRB resulting from endothelial dysfunction is one of the initial alterations in diabetic retinal disease. It is this alteration of the iBRB that leads to diabetic macular oedema, the most frequent cause of vision loss due to diabetes, and that triggers most of the pathological changes that lead to retinopathy progression (see Figure 4) .
In AMD, it is the integrity of the outer BRB that keeps the choroidal vascular response from invading the retina and changing dry AMD into wet AMD, which results in rapid vision loss (see Figure 5) . From the viewpoint of drug delivery, designing drugs (including peptides)
with greater lipophilicity to enhance BRB permeability seems to be an easy approach. However, such a strategy would not only increase permeation into tissues other than the retina, but also decrease bioavailability due to the hepatic first-pass metabolism in the case of oral administration. Accordingly, for the development of retina-specific drug delivery systems for neuroactive drugs, the most effective approach is to utilize the specific transport mechanisms active at the BRB. That would mean designing drugs that mimic the substrates to be taken by particular transporters or receptors existing in the BRB. through intravitreal injections to a large number of patients without significant side effects and demonstrating good acceptance by the patients. Intravitreal injections can achieve high drug concentrations in the vitreous humour and retina, preserving BRB integrity and its crucial protective function. At present, the major challenge appears to be the need to decrease the number of intravitreal injections, which, in the case of anti-VEGF treatments, are given every six weeks to maintain efficacy. The search for safe slow-delivery devices or implantable biomaterials is ongoing, but the invasive approach to retinal disease treatment appears to be an effective way of rapidly reaching therapeutic levels in the retina in the presence of a functioning BRB. n
